Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CPHTSE:HLSNASDAQ:OGICVE:RX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHCipher PharmaceuticalsC$12.77-0.7%C$12.83C$8.01▼C$19.69C$229.26M1.230,338 shs16,179 shsHLSHLS TherapeuticsC$4.79+0.4%C$4.71C$3.00▼C$5.23C$106.57M1.0713,365 shs6,301 shsOGIOrganigram Global$1.35-3.6%$1.28$0.85▼$2.08$180.82M1.37660,026 shs540,412 shsRXBioSyentC$11.79+1.3%C$11.38C$9.20▼C$12.13C$134.85M0.934,422 shs654 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHCipher Pharmaceuticals0.00%+0.08%+2.98%+1.59%+51.48%HLSHLS Therapeutics0.00%-3.43%-3.23%+2.79%+42.56%OGIOrganigram Global0.00%+4.65%-2.17%+31.07%-11.48%RXBioSyent0.00%+0.77%+0.43%+5.74%+15.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPHCipher Pharmaceuticals1.5103 of 5 stars2.40.00.00.01.91.71.3HLSHLS TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global1.3786 of 5 stars0.01.00.00.03.80.02.5RXBioSyentN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHCipher Pharmaceuticals 2.75Moderate BuyC$14.7515.51% UpsideHLSHLS Therapeutics 2.00HoldC$4.50-6.05% DownsideOGIOrganigram Global 3.00BuyN/AN/ARXBioSyent 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OGI, HLS, CPH, and RX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025CPHCipher PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHoldC$12.50(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHCipher PharmaceuticalsC$19.03M12.04C$3.62 per share3.53C$3.96 per share3.22HLSHLS TherapeuticsC$40.13M2.66C$0.31 per share15.22C$2.51 per share1.91OGIOrganigram Global$117.47M1.54N/AN/A$2.07 per share0.65RXBioSyentC$34.06M3.96C$3.83 per share3.07C$3.22 per share3.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHCipher PharmaceuticalsC$11.41MC$0.9114.10∞N/A59.92%17.93%7.90%N/AHLSHLS Therapeutics-C$15.53M-C$1.00N/A∞N/A-38.70%-25.27%-2.89%N/AOGIOrganigram Global-$33.39M$0.1013.50N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)RXBioSyentC$7.02MC$0.6219.13∞N/A20.60%20.01%12.86%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHCipher PharmaceuticalsN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.18%N/AN/A N/AOGIOrganigram GlobalN/AN/AN/AN/AN/ARXBioSyentC$0.181.53%N/A29.21%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHCipher Pharmaceuticals41.222.002.67HLSHLS Therapeutics86.501.561.01OGIOrganigram GlobalN/A3.421.90RXBioSyent2.903.926.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHCipher Pharmaceuticals1.38%HLSHLS Therapeutics65.20%OGIOrganigram Global34.63%RXBioSyent1.37%Insider OwnershipCompanyInsider OwnershipCPHCipher Pharmaceuticals42.00%HLSHLS Therapeutics0.37%OGIOrganigram Global0.09%RXBioSyent33.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHCipher Pharmaceuticals517.95 millionN/ANot OptionableHLSHLS Therapeutics9122.25 millionN/ANot OptionableOGIOrganigram Global860133.94 million133.82 millionOptionableRXBioSyentN/A11.44 millionN/ANot OptionableOGI, HLS, CPH, and RX HeadlinesRecent News About These CompaniesBiosyent Inc. Stock Price HistoryJune 19, 2025 | investing.comBioSyent (CVE:RX) Has Announced A Dividend Of CA$0.05May 19, 2025 | finance.yahoo.comHere's Why We Think BioSyent (CVE:RX) Is Well Worth WatchingMay 15, 2025 | finance.yahoo.comCould The Market Be Wrong About BioSyent Inc. (CVE:RX) Given Its Attractive Financial Prospects?April 18, 2025 | finance.yahoo.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive YearApril 1, 2025 | markets.businessinsider.comFAX Capital Corp. Sells 112,400 Shares of BioSyent Inc. (CVE:RX) StockDecember 24, 2024 | insidertrades.comInvesting in BioSyent (CVE:RX) five years ago would have delivered you a 110% gainDecember 15, 2024 | uk.finance.yahoo.comBioSyent Inc. (CVE:RX) Senior Officer Sells C$55,628.75 in StockDecember 13, 2024 | insidertrades.comInsider Selling: BioSyent Inc. (CVE:RX) Insider Sells 65,000 Shares of StockNovember 27, 2024 | insidertrades.comBioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 230,800 SharesNovember 26, 2024 | insidertrades.comBioSyent Inc. (RX.V)November 24, 2024 | finance.yahoo.comBioSyent Inc. (CVE:RX) Will Pay A CA$0.045 Dividend In Four DaysNovember 24, 2024 | finance.yahoo.comCalculating The Fair Value Of BioSyent Inc. (CVE:RX)November 22, 2024 | finance.yahoo.comBioSyent Inc. (BIOYF)November 21, 2024 | finance.yahoo.comBioSyent Inc.November 13, 2024 | wsj.comAMD RDNA 4: everything we know so far about the RX 8000 seriesNovember 1, 2024 | digitaltrends.comDBioSyent Inc.'s (CVE:RX) Stock Is Going Strong: Is the Market Following Fundamentals?October 24, 2024 | finance.yahoo.comSaatva Rx Mattress Review 2024: A Luxury Bed Designed for People With Chronic Health ConditionsOctober 1, 2024 | cnet.comShould You Be Adding BioSyent (CVE:RX) To Your Watchlist Today?September 26, 2024 | finance.yahoo.comInsider Selling: BioSyent Inc. (CVE:RX) Director Sells 2,320 Shares of StockSeptember 24, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesSoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Wall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPEGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractOGI, HLS, CPH, and RX Company DescriptionsCipher Pharmaceuticals TSE:CPHC$12.77 -0.09 (-0.70%) As of 06/27/2025 04:00 PM EasternCipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.HLS Therapeutics TSE:HLSC$4.79 +0.02 (+0.42%) As of 06/27/2025 03:47 PM EasternHLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.Organigram Global NASDAQ:OGI$1.35 -0.05 (-3.57%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.85%) As of 06/27/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.BioSyent CVE:RXC$11.79 +0.15 (+1.29%) As of 06/27/2025 01:56 PM EasternBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
